Who is sponsoring NCT04273854?

NCT04273854 is sponsored by University of Oxford.

What condition does NCT04273854 study?

NCT04273854 studies Pre-Eclampsia, Gestational Hypertension.

Is NCT04273854 still recruiting?

NCT04273854 is currently active, enrolled. Last updated 22 October 2021.

Last reviewed 2021-10-22 · How we verify

NCT04273854: POP-HT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Physician Optimised Post-partum Hypertension Treatment Trial

Active, enrolled NA Last updated 22 October 2021

What this trial tests

NA trial testing OMRON Evolv® blood pressure monitor (Blue-tooth® enabled) & Proprietary Smartphone POP-HT app® in Pre-Eclampsia in 200 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

21 February 2020

Primary endpoint
1 April 2022

1 December 2030

Quick facts

Lead sponsor	University of Oxford
Phase	NA
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	prevention
Enrollment	200
Start date	21 February 2020
Primary completion	1 April 2022
Estimated completion	1 December 2030
Sites	2 locations across United Kingdom

Drugs / interventions tested

OMRON Evolv® blood pressure monitor (Blue-tooth® enabled) & Proprietary Smartphone POP-HT app®

Conditions studied

Pre-Eclampsia — all drugs for Pre-Eclampsia →
Gestational Hypertension — all drugs for Gestational Hypertension →

Sponsor

University of Oxford

Who can join

18 and older, female only, with Pre-Eclampsia or Gestational Hypertension. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

It has been shown in a pilot randomised controlled study \[SNAP-HT \[4\]; REC 14/SC/1316\] that blood pressure self-management during the post-partum period after hypertensive pregnancies, results in lower blood pressure after six months; even when medication has been stopped. The team now want to assess whether this blood pressure reduction can be reproduced in a larger, randomised, study (data analysis blinded) and whether the blood pressure lowering has additional benefits in terms of other cardiovascular and cerebrovascular changes known to occur in women who have had a hypertensive pregnancy. The investigators therefore plan to run a trial of self-management in the post-partum period, using updated Blue-tooth® enabled blood pressure monitoring coupled to physician-assisted dose titration to further advance the self-management aspect of the intervention. The physicians will be specialist clinicians who form part of the research team. The investigators will measure additional structural and functional end organ differences, using magnetic resonance imaging of the brain and heart as well as echocardiography and retinal imaging. This will provide insight into the impact of post-partum blood pressure control on the maternal cardiovascular system and how this associates with blood pressure changes. Together, these studies will help refine future intervention strategies in this cohort of patients.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

Short-Term Postpartum Blood Pressure Self-Management and Long-Term Blood Pressure Control: A Randomized Controlled Trial.
Kitt JA, Fox RL, Cairns AE, Mollison J, et al · · 2021 · cited 81× · PMID 34176288 · DOI 10.1161/hypertensionaha.120.17101
Long-Term Blood Pressure Control After Hypertensive Pregnancy Following Physician-Optimized Self-Management: The POP-HT Randomized Clinical Trial.
Kitt J, Fox R, Frost A, Shanyinde M, et al · · 2023 · cited 73× · PMID 37950919 · DOI 10.1001/jama.2023.21523
Cardiac Remodeling After Hypertensive Pregnancy Following Physician-Optimized Blood Pressure Self-Management: The POP-HT Randomized Clinical Trial Imaging Substudy.
Kitt J, Krasner S, Barr L, Frost A, et al · · 2024 · cited 37× · PMID 37950907 · DOI 10.1161/circulationaha.123.067597
Postpartum blood pressure self-management following hypertensive pregnancy: protocol of the Physician Optimised Post-partum Hypertension Treatment (POP-HT) trial.
Kitt J, Frost A, Mollison J, Tucker KL, et al · · 2022 · cited 16× · PMID 35197335 · DOI 10.1136/bmjopen-2021-051180
Brain Volumes After Hypertensive Pregnancy and Postpartum Blood Pressure Management: A POP-HT Randomized Clinical Trial Imaging Substudy.
Lapidaire W, Kitt J, Krasner S, Bateman PA, et al · · 2026 · PMID 41490362 · DOI 10.1001/jamaneurol.2025.5145
Impact of Blood Pressure Self-Management on Vascular Remodeling After Hypertensive Pregnancy.
Kitt J, Biasiolli L, Krasner S, Bateman PA, et al · · 2025 · PMID 40905148 · DOI 10.1161/hypertensionaha.125.24854
Subclinical Postpartum Renal Structure After Hypertensive Pregnancy Disorders.
Cutler HR, Kitt J, Sattwika PD, Finnigan LEM, et al · · 2025 · PMID 40886083 · DOI 10.1161/hypertensionaha.125.25130

Verify or expand the search:

Other recruiting trials for Pre-Eclampsia

Currently open trials in the same condition.

NCT07245056 — Fetal Fornix and Hippocampus in Pregnant Women With Early-Onset Preeclampsia · NA · recruiting
NCT07187596 — Mortality Outcome of Controlled Hypertension · active not recruiting
NCT06893510 — Virtual Reality-Based and Face-to-Face Relaxation Programs in Pregnant Women With Preeclampsia · NA · recruiting
NCT06122220 — Optic Nerve Sheath Measurement and Angiogenic Factors in Patients With Pre-eclampsia. · NA · recruiting
NCT06779916 — Autophagy/Apoptosis Balance in Placental Vascular Pathologies · recruiting

Other University of Oxford trials

Trials by the same sponsor.

NCT05380388 — A Safety, Immunogenicity and Efficacy Study of PvRII/Matrix-M in Healthy Thai Adults Living in Thailand ( MIST3 ) · Phase 2 · not yet recruiting
NCT07470424 — A Clinical Study of Piperaquine, Pyronaridine, and Artesunate Administered in Combination in Healthy Adults · Phase 1 · not yet recruiting
NCT07345910 — Environment, Pathogens, and Host Interactions in Melioidosis · not yet recruiting
NCT07434973 — Stratification and Treatment in Early Psychosis Study - PROMOTE · Phase 3 · not yet recruiting
NCT07460401 — 'Do Patient Characteristics Associate With Poor Outcome With Femoral Acetabular Impingement Syndrome (FAIS) Following Ph · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04273854 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Oxford
Last refreshed: 22 October 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04273854.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing